Lee Brown, healthcare sector lead at Third Bridge, discussed Pfizer’s outlook during an interview on BNN Bloomberg. Pfizer forecasts 2025 sales between $61 billion and $64 billion, aligning with analyst expectations, and anticipates profits of $2.80 to $3 per share. Despite a 12% decline this year, shares rose 4.8% following the announcement. Activist investor Starboard Value has criticized Pfizer’s management and investments. CEO Albert Bourla has announced cost cuts totaling $6 billion and appointed Chris Boshoff as chief scientific officer. Bourla also mentioned a dinner with Donald Trump and Robert F. Kennedy Jr., emphasizing collaboration on health initiatives.